25,669 Axon Enterprise, Inc $AXON Shares Purchased by 180 Wealth Advisors LLC

Key Points

• 180 Wealth Advisors increased its Axon stake by 202.8% in the third quarter, buying 25,669 shares. It held 38,324 shares worth about $16.2 million, representing 1.5% of its portfolio.
• Axon’s latest quarter showed strong year-over-year growth, with revenue up 27.8%, but earnings and revenue missed analyst expectations: EPS was $1.72 versus $1.89 expected, and revenue was $908.55 million versus $934.33 million expected.
• Axon shares were reported down 18.2%, while analysts’ views remained mixed: the consensus rating was “Moderate Buy,” though Craig Hallum downgraded the stock to Hold.

180 Wealth Advisors LLC lifted its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 202.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 38,324 shares of the biotechnology company's stock after purchasing an additional 25,669 shares during the period. Axon Enterprise accounts for 1.5% of 180 Wealth Advisors LLC's investment portfolio, making the stock its 9th biggest holding. 180 Wealth Advisors LLC's holdings in Axon Enterprise were worth $16,193,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently modified their holdings of AXON. State Street Corp raised its stake in Axon Enterprise by 5,700.2% in the 2nd quarter. State Street Corp now owns 213,561,844 shares of the biotechnology company's stock valued at $119,724,905,000 after acquiring an additional 209,879,882 shares during the period. Envestnet Asset Management Inc. increased its stake in shares of Axon Enterprise by 18,050.2% in the second quarter. Envestnet Asset Management Inc. now owns 13,200,075 shares of the biotechnology company's stock worth $7,400,094,000 after purchasing an additional 13,127,348 shares in the last quarter. Robeco Institutional Asset Management B.V. increased its stake in shares of Axon Enterprise by 391,214.9% in the third quarter. Robeco Institutional Asset Management B.V. now owns 6,988,884 shares of the biotechnology company's stock worth $2,952,943,000 after purchasing an additional 6,987,098 shares in the last quarter. Assenagon Asset Management S.A. raised its position in shares of Axon Enterprise by 5,022.8% in the third quarter. Assenagon Asset Management S.A. now owns 4,266,589 shares of the biotechnology company's stock valued at $1,802,719,000 after purchasing an additional 4,183,302 shares during the period. Finally, The Manufacturers Life Insurance Company raised its position in shares of Axon Enterprise by 8,432.6% in the second quarter. The Manufacturers Life Insurance Company now owns 3,537,957 shares of the biotechnology company's stock valued at $1,983,414,000 after purchasing an additional 3,496,493 shares during the period. Institutional investors own 79.08% of the company's stock.

Trending Headlines about Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q3 revenue reached a record $909 million, up 28% year over year, while software and services revenue rose 43%. Axon also reported AI annual recurring revenue above $100 million, signaling continued demand for its software and AI offerings. Axon Q3 results
• Neutral Sentiment: Axon committed an additional $1.2 billion to drone maker Skydio, bringing its stake to 37% and making it Skydio’s exclusive public-safety distributor in the U.S. and Canada. The move could expand Axon’s Drone as First Responder business, but its scale also raises investment and execution risks. Reuters: Axon invests in Skydio
• Negative Sentiment: Q3 adjusted earnings of $1.72 per share and revenue of $908.55 million fell short of analyst expectations. Axon’s 2026 revenue forecast was reduced to $3.6 billion from a consensus of about $3.7 billion; its Q4 revenue guidance also came in below estimates. The company cited delays in federal counter-drone projects, while margin pressure added to concerns. Zacks: Q3 miss and outlook
• Negative Sentiment: Several analysts lowered price targets after the results, and Craig Hallum downgraded AXON from Buy to Hold, adding to pressure on investor sentiment. Benzinga: analyst forecast changes
• Negative Sentiment: A class-action lawsuit over Axon’s license-plate surveillance practices is a potential additional legal and reputational overhang. Class-action announcement

Insiders Place Their Bets

In other news, President Joshua Isner sold 16,775 shares of the business's stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $574.43, for a total transaction of $9,636,063.25. Following the completion of the transaction, the president owned 296,974 shares of the company's stock, valued at approximately $170,590,774.82. The trade was a 5.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jeffrey Kunins sold 9,605 shares of the stock in a transaction on Friday, August 21st. The stock was sold at an average price of $626.70, for a total transaction of $6,019,453.50. Following the completion of the transaction, the insider directly owned 97,761 shares in the company, valued at $61,266,818.70. The trade was a 8.95% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 37,397 shares of company stock valued at $21,234,034 in the last ninety days. Corporate insiders own 4.20% of the company's stock.

Axon Enterprise Trading Down 18.2%

Shares of AXON opened at $313.00 on Friday. The business's 50-day moving average price is $441.53 and its 200-day moving average price is $475.20. Axon Enterprise, Inc has a twelve month low of $307.00 and a twelve month high of $665.07. The stock has a market cap of $25.43 billion, a PE ratio of 100.32, a P/E/G ratio of 5.95 and a beta of 1.48. The company has a quick ratio of 1.80, a current ratio of 2.15 and a debt-to-equity ratio of 0.47.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $1.72 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.89 by ($0.17). Axon Enterprise had a return on equity of 3.95% and a net margin of 7.56%. The firm had revenue of $908.55 million during the quarter, compared to analysts' expectations of $934.33 million. During the same period in the previous year, the company posted $1.17 earnings per share. The company's quarterly revenue was up 27.8% compared to the same quarter last year. On average, equities analysts forecast that Axon Enterprise, Inc will post 2.10 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Piper Sandler restated an "overweight" rating and set a $540.00 price target (down from $561.00) on shares of Axon Enterprise in a research note on Friday. TD Cowen reduced their price objective on shares of Axon Enterprise from $825.00 to $800.00 and set a "buy" rating for the company in a research note on Monday, October 26th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Axon Enterprise in a research note on Tuesday. Argus boosted their target price on shares of Axon Enterprise from $460.00 to $600.00 and gave the company a "buy" rating in a report on Thursday, September 3rd. Finally, Craig Hallum downgraded Axon Enterprise from a "buy" rating to a "hold" rating and set a $390.00 target price on the stock. in a research report on Friday. Thirteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $631.35.

About Axon Enterprise

Axon Enterprise develops technology and services for public safety agencies. Its products include TASER conducted-energy weapons, body-worn and in-car cameras, and related hardware designed to support law enforcement and other safety professionals.

The company also provides cloud-based software for managing digital evidence, records and operational workflows. Its Axon Evidence platform helps agencies store, organize and share video and other evidence, while its broader software offerings include tools for dispatch and records management.

Founded in 1993 as TASER International, the company adopted the name Axon Enterprise in 2017 as it expanded beyond conducted-energy weapons into connected devices and software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.